Juan C. Vázquez-Ucha

Post Doctoral Researcher in Institute of Biomedical Research of A Coruña (INIBIC)

[Bibliosaude @Bibliosaude]

Nanoemulsion-based colistin for pulmonary delivery: Enhanced antibacterial efficacy against Acinetobacter baumannii #PublicaSergas #IDIS #INIBIC https://t.co/6cn4L1XjBC

[Gonzalez-Bello group @GonzalezBello_C]

Thriller to see our latest article published in antimicrobial agents chemotherapy selected for the cover of the journal. Another excellent collaboration between @ArcaSuarez90 @GonzalezBello_C @microchuac
Details👇
https://t.co/54OQzbWDKA

[Wataru Hayashi / 林 航 @DraWataru]

【Stenotrophomonas maltophilia】

＊How do I manage a patient with S. maltophilia infection?
(https://t.co/EY0TO8V8M1)

＊Global mapping of antibiotic resistance rates among clinical isolates of S. maltophilia: a systematic review and meta-analysis
(https://t.co/dKcvrOapLn)

[Wataru Hayashi / 林 航 @DraWataru]

【Stenotrophomonas maltophilia】

＊Rationale for contemporary antimicrobial treatment of Stenotrophomonas maltophilia: a narrative review
(https://t.co/A4O9V5diHv)

＊Stenotrophomonas maltophilia virulence: a current view
(https://t.co/xD2ckkNR0O)

[Juan C. Vázquez-Ucha @jcvazquezucha]

@microchuac @german_bou @Alex_Beceiro @ArcaSuarez90

[Juan C. Vázquez-Ucha @jcvazquezucha]

We are pleased to share our latest article in Antimicrobial Agents and Chemotherapy, which evaluates the activity of the novel polymyxin SPR206 against both colistin-susceptible and colistin-resistant Acinetobacter baumannii. https://t.co/c9AzVxBp2p

[Gonzalez-Bello group @GonzalezBello_C]

Check the efficacy of recent drug against challeging carbapenamases @GonzalezBello_C @microchuac
Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors https://t.co/LO2aIiO4jx

[Juan C. Vázquez-Ucha @jcvazquezucha]

Thrilled to see our latest work published in #AAC, evaluating the activity of novel beta-lactamase inhibitors against the widely distributed carbapenemase OXA-48. Great work team! https://t.co/fIw1vP00HP

[Juan C. Vázquez-Ucha @jcvazquezucha]

Our last work on the activity and resistance mechanisms of third generation tetracyclines against CPEs and A. baumannii is now available online in Biomedicine & Pharmacotherapy

https://t.co/aw9HY02ORt

@microchuac @german_bou @Alex_Beceiro

[Jorge Arca Suárez @ArcaSuarez90]

We are very pleased to see our latest article in AAC, reinforcing the microbiological positioning of imipenem/relebactam over carbapenem monotherapy to treat K. pneumoniae infections with CZA-resistant KPC variants and collateral carbapenm susceptibility

https://t.co/6aU1Z72a6q

[Juan C. Vázquez-Ucha @jcvazquezucha]

📢 A new Special Issue is open for submissions: "β-Lactams and β-Lactamase Inhibitors: Recent Advances"
📝 hashtag#PharmaceuticalsMDPI (IF 4.3, Q1)
⏰Deadline: 30 Apr 2025
🎓Guest Editor : Dr. Juan C. Vázquez-Ucha
📖Find out more at: https://t.co/9MCijT3FDt

[Jorge Arca Suárez @ArcaSuarez90]

Our latest work on the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors (e.g., taniborbactam, xeruborbactam) in double-carbapenemase-producing Enterobacterales is available in AAC!! https://t.co/7DRuaRHPL4

[BSAC @BSACandJAC]

Comprehensive comparative analysis of the stability of cefiderocol & new β-lactam/β-lactamase inhibitor combinations for P. aeruginosa—promising data against this continuously evolving threat
https://t.co/K8040vsER1
@ArcaSuarez90 @german_bou @Luciagpinto @OUPMedicine #JACNews

[IDSA @IDSAInfo]

NEW #IDSAGuidelines on the treatment of antimicrobial resistant gram-negative infections! This fourth updated guidance document focuses on infections caused by:

• Extended-spectrum β-lactamase-producing Enterobacterales
• AmpC β- lactamase-producing Enterobacterales
• carbapenem-resistant Enterobacterales
• Pseudomonas aeruginosa with difficult-to-treat resistance
• carbapenem-resistant Acinetobacter baumannii
• Stenotrophomonas maltophilia

Read: https://t.co/pRj2pVyR6e

[SEIMC @SEIMC_]

📡 ¿Te gustaría actualizar tus conocimientos en #RAM?

Accede de la mano de @GemaraSeimc a una formación que te permitirá cuidar y optimizar el uso de #antibióticos

Más información e inscripciones 👇

[Instituto de Salud Carlos III (ISCIII) @SaludISCIII]

Una investigadora posdoctoral del #ISCIII logra una beca europea @ESCMID para estudiar el desarrollo de una vacuna frente a infecciones bacterianas multirresistentes.

👩‍🔬 @Eva_Gato trabaja en nuestro Centro Nacional de Microbiología.

📰 #NoticiasISCIII ➡️ https://t.co/svW6aOLpyX

[Gonzalez-Bello group @GonzalezBello_C]

Interested in bacterial resistance to β-lactam antibiotics?
Take a look of our recent contribution in the field 👇
@GonzalezBello_C @UniversidadeUSC @ciqususc @microchuac

https://t.co/mEgIE1bnP5

[Antibiotics MDPI @antibioticsmdpi]

📢📢📢#Call for #Reading. We have Published 6 Papers in the Special Issue: “#Bacterial #Pathogenesis and #Antimicrobial #Strategy”

📝Guest Edited by Dr. Juan Carlos Vázquez Ucha and Dr. Marta Martínez Guitián

😊 Welcome to read at 👉 https://t.co/jpf49YxZV5

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕️🔥 Position paper @CMIJournal
Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-@ESCMID/ ISARPAE Group #idxposts #bookmark #mustread
https://t.co/4utUKPsjoz

[Smani Lab مختبر سمعاني @smani_lab]

We are #hiring! Looking for a new PhD student to work on bacterial intracellular persistence in the Bacterial Infections and Treatments Lab at the CABD (Seville,Spain). Expected date to start is September 2024.
Please RT! #PhDPosition @CABD_UPO_CSIC @pablodeolavide @ibis_sevilla